Please ensure Javascript is enabled for purposes of website accessibility

Why AcelRx Pharmaceuticals Stock Is Sinking Today

By Keith Speights - Jan 20, 2021 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a public stock offering.

What happened

Shares of AcelRx Pharmaceuticals (ACRX 1.66%) were trading down by 16% as of 11:40 a.m. EST on Wednesday after the company announced the pricing of a public stock offering. AcelRx plans to sell 14.5 million new shares in a transaction expected to generate gross proceeds of around $27.5 million.

So what

Secondary stock offerings cause stocks to fall for one simple reason: They dilute the value of existing shares. In addition, in AcelRx's case, the biotech company intends to sell its new shares at a 19% discount to its closing price on Tuesday. It's not surprising, therefore, that its share price has fallen to close to that level.

$1 bill folded into an arrow pointing down

Image source: Getty Images.

There's a silver lining with the transaction, though. AcelRx will raise additional cash that it needs. Management said it plans to use those funds for "working capital and general corporate purposes, including commercialization activities, general and administrative expenses, research and development expenses, capital expenditures, and for making scheduled payments under its debt facility." That pretty much covers all of the spending areas for the biotech company.

The share price slides driven by secondary stock offerings are often only temporary if investors have reasons to be optimistic about the future of the company in question. AcelRx thinks that its progress in commercializing its sublingual opioid painkiller, Dsuvia, could provide such reasons for confidence.

Now what

The main thing for investors to watch now with AcelRx will be its fourth-quarter update, which is expected in February. AcelRX has already begun to receive initial stocking orders for Dsuvia from the U.S. Department of Defense. These should boost the company's sales over the coming quarters.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AcelRx Pharmaceuticals, Inc. Stock Quote
AcelRx Pharmaceuticals, Inc.
$0.23 (1.66%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.